# Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure

> **NCT01214096** · PHASE3 · TERMINATED · sponsor: **Zensun Sci. & Tech. Co., Ltd.** · enrollment: 15 (actual)

## Conditions studied

- Chronic Heart Failure

## Interventions

- **DRUG:** rhNRG-1
- **DRUG:** rhNRG-1
- **DRUG:** rhNRG-1
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01214096
- **Lead sponsor:** Zensun Sci. & Tech. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-07
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** The same protocol has been launched in United States.
- **Last updated:** 2017-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01214096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01214096, "Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01214096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*